Biodexa Announces It Has Been Awarded Additional $3M Grant From CPRIT To Support Registrational eRapa Phase 3 Program In FAP Bringing Total CPRIT Grant Funding For eRapa Phase 3 Program To $20M

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP

Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced its collaboration partner, Rapamycin Holdings, Inc. d/b/a Emtora Biosciences ("Emtora") has been awarded an additional grant of $3.0 million from the Cancer Prevention & Research Institute of Texas ("CPRIT"). This award brings the total grant awarded by CPRIT to support the registrational Phase 3 program of eRapa in familial adenomatous polyposis ("FAP") to $20.0 million.

"We are sincerely thankful to Emtora, our collaboration partner for their work in preparing the application and, of course, to CPRIT for this additional award." said Stephen Stamp, CEO and CFO of Biodexa Pharmaceuticals PLC. "This grant will enable us to include more sites, speed up recruitment and, subject to regulatory approval, bring this medicine to patients who currently have no option other than surgical resection of part or all of their GI tract."